A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patients with HER2-positive cancers. However, the development of drug resistance adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shengnan, Zhang, Jing, Yan, Yongxiang, Yao, Xudong, Fang, Lijuan, Xiong, Hui, Liu, Yang, Chu, Qian, Zhou, Pengfei, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694677/
https://www.ncbi.nlm.nih.gov/pubmed/31412896
http://dx.doi.org/10.1186/s13046-019-1354-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694677/
https://www.ncbi.nlm.nih.gov/pubmed/31412896
http://dx.doi.org/10.1186/s13046-019-1354-1

Ejemplares similares